1261453-93-3 Usage
Uses
Used in Chemical Synthesis:
(6-chloronaphthalen-2-yl)methanamine is used as a building block for the synthesis of various organic compounds, contributing to the creation of a diverse range of chemical products.
Used in Pharmaceutical Industry:
(6-chloronaphthalen-2-yl)methanamine is used as an intermediate in the development of pharmaceuticals, potentially aiding in the production of new drugs with specific therapeutic applications.
Used in Research and Development:
In the field of research and development, (6-chloronaphthalen-2-yl)methanamine is utilized for studying the properties and reactions of aromatic amines, which can lead to advancements in chemical and material sciences.
Used in Environmental Monitoring:
(6-chloronaphthalen-2-yl)methanamine may also be employed in environmental monitoring and analysis, helping to detect and assess the presence of similar compounds in the environment, thus contributing to pollution control and ecological preservation efforts.
Check Digit Verification of cas no
The CAS Registry Mumber 1261453-93-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,1,4,5 and 3 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1261453-93:
(9*1)+(8*2)+(7*6)+(6*1)+(5*4)+(4*5)+(3*3)+(2*9)+(1*3)=143
143 % 10 = 3
So 1261453-93-3 is a valid CAS Registry Number.
1261453-93-3Relevant academic research and scientific papers
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 001126; 001128, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 001168; 001169; 001171, (2019/07/17)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
